A Humanized IFN-γ Mouse Model Reveals Skin Eschar Formation, Enhanced
Susceptibility and Scrub Typhus Pathogenesis

Running title: Genetically engineered humanized mouse model in scrub typhus

Ryan H. Cho[a], Lihai Gao[a], Casey Gonzales[b], Dario Villacreses[a], Emmett A. Dews[a], Hema P.
Narra[b], Hui Wang[b], Lynn Soong[a,b,c,d,#], Yuejin Liang[a,c,d,#]

[a] Department of Microbiology and Immunology, University of Texas Medical Branch,
Galveston, Texas, USA

[b] Department of Pathology, University of Texas Medical Branch, Galveston, Texas, USA

[c] Institute for Human Infections and Immunity, University of Texas Medical Branch, Galveston,
Texas, USA

[d] Center for Tropical Diseases, University of Texas Medical Branch, Galveston, Texas, USA

#Address correspondence to: Lynn Soong, lysoong@utmb.edu and Yuejin Liang,
yu2liang@utmb.edu

18
19
20
21 Key words: *Orientia*, interferon, eschar formation, intradermal inoculation, humanized mice

26
27

Abstract

Scrub typhus, caused by *Orientia tsutsugamushi* (*Ot*) bacteria, is a serious acute febrile illness associated with significant mortality. An estimated one million cases occur annually, with more than one billion people at risk. No effective vaccine is currently available, largely due to the complex *Ot* strain diversity and an incomplete understanding of protective immune mechanisms. To overcome these challenges, there is a critical need for a suitable animal model that mimics human disease through the natural route of infection via mites. Here, we report for the first time that a genetically engineered humanized mouse strain (with triple knockout/knock-in of IFN-γ and its receptors), exhibits increased susceptibility to intradermal *Ot* infection compared to wild-type (WT) mice. This is evidenced by greater body weight loss, elevated bacterial burden, and reduced expression of interferon-stimulated genes (ISGs). Humanized mice exhibit pronounced biochemical abnormalities and tissue pathology accompanied by dysregulated T cell and neutrophil responses following infection. Notably, these immunocompetent mice develop skin eschar-like lesions resembling those observed in human patients. Overall, our study introduces a promising humanized mouse model to dissect the immunopathogenesis of scrub typhus and evaluate future vaccine candidates.

Author Summary

Scrub typhus is a serious disease caused by the obligately intracellular bacterium *Ot* that spreads

to humans through the bite of larval mites called chiggers. It affects over a million people each

year, primarily in Asia, and can lead to life-threatening complications. Unfortunately, we still

lack a clear understanding of how this infection causes disease, partly because there is not a good

laboratory model that closely reflects how humans respond to infection. Our recent reports have

suggested an important role of IFN-γ in host protection against *Ot* infection. In this study, we

used a new genetically modified mouse strain that carries human IFN-γ signaling in place of its

mouse counterpart. We found that these humanized mice are more vulnerable to infection,

develop skin eschar lesions like those in patients, and show signs of systemic inflammation and

organ damage. Their immune response also resembled what has been observed in human

patients. This new mouse model can help scientists better understand the mechanisms as to how

this bacterial species causes severe disease outcomes in patients. Once those mechanisms are

understood, this mouse model will serve a further purpose as a tool for testing new vaccines and

treatments to aid humans at-risk for scrub typhus.

Introduction

Orientia tsutsugamushi (*Ot*) is an obligately intracellular bacterium that causes scrub typhus in humans. An estimated one million cases occur annually, with over one billion people at risk, mostly within the "tsutsugamushi triangle", which extends from Pakistan in the west to far eastern Russia in the east to northern Australia in the south(1, 2). *Ot* is primarily transmitted to humans through the bite of infected chigger mites of the *Leptotrombidium* genus, such as *Leptrotrombidium palpale,* a reservoir which maintains the bacterium through transovarial transmission(3). The clinical manifestations of scrub typhus include fever, headache, myalgia, vomiting, lymphadenopathy, and the characteristic eschar at the site of the chigger bite(4-6). In severe cases, bacterial dissemination to multiple organs can result in life-threatening complications such as respiratory failure, disseminated intravascular coagulation, meningitis, and encephalitis(7-9). Although traditionally endemic to countries within the tsutsugamushi triangle, scrub typhus cases have been reported in Africa, South America, and the Middle East(10). Notably, a recent discovery of *Orientia* DNA in chiggers in North Carolina raises concerns about potential emergence in the United States(11). Currently, there is no licensed vaccine for scrub typhus, partly due to a limited understanding of host-pathogen interactions and the extensive antigenic diversity among *Orientia* strains(12, 13). This lack of immunological insight leaves us ill-prepared to combat this neglected mite-borne disease, underscoring the urgent need to elucidate the mechanisms underlying *Ot* pathogenesis.

Animal models that closely recapitulate human scrub typhus are essential for advancing immunological studies and evaluating vaccine candidates. Reported animal models include intraperitoneal, intravenous, and intradermal routes of infection in mice, as well as intradermal

and live chigger challenge models in non-human primates(14-22). The intraperitoneal and

intravenous inoculation models, which involve the direct introduction of bacteria into the

peritoneal cavity or bloodstream, respectively, allow for systemic dissemination of the bacteria

and mimic severe scrub typhus and lethal outcomes(21, 23, 24). However, these routes bypass

the natural mode of transmission, in which bacteria are introduced by the bite of an infected

chigger mite and disseminate via the lymphatic system before bloodstream invasion(22, 25). The

intradermal or subcutaneous mouse models, which better mimic the natural route of *Ot* infection,

are commonly used to study bacterial dissemination and pathogenesis (15, 18, 19, 25-28). These

models, though, are not effective for modeling severe scrub typhus disease. While intradermal

infection leads to systemic bacterial dissemination and elicits host protective immune responses,

immunocompetent mice (inbred C57BL/6 or outbred CD-1 mice, etc.) are largely resistant and

develop only mild disease or no major symptoms(15, 19, 28). This suggests that mice are capable

of mounting stronger protective immune responses against *Ot* than humans. Thus, developing a

susceptible and immunocompetent mouse model is critical for investigating bacterial

dissemination in humans, elucidating protective host immunity, and evaluating vaccine

candidates against human relevant disease states.

It is known that *Ot* infection elicits strong type 1 immunity in both patients and animal models

(29-32). We recently demonstrated that mice deficient in IFN-γ receptor signaling are highly

susceptible to intradermal *Ot* infection, exhibiting 100% lethality even at very low infectious

doses(25). In addition, these deficient mice display eschar-like lesions that are not observed in

immunocompetent mice(25), highlighting the role of IFN-γ signaling in host protection against

Ot infection. Although *Ifngr1*[-/-] mice are highly susceptible to *Ot* infection, their

immunocompromised status limits their ability to model the complex and coordinated immune

responses observed during natural infections. As a result, they are not suitable for comprehensive

studies of immunopathogenesis, vaccine development, or host protective immunity. Given that

humans with intact IFN-γ signaling remain susceptible to *Ot*, we hypothesize that human

susceptibility may stem from comparatively weaker IFN-γ signaling than that observed in mice.

Although IFN-γ signaling is functionally conserved between humans and mice, species-specific

differences may lead to differential regulation of downstream genes and contribute to the

observed differences in susceptibility to infection (33, 34).

In this study, we establish a novel mouse model of scrub typhus by using a genetically

engineered humanized mouse strain that lacks murine IFN-γ signaling but is reconstituted with

functional human IFN-γ signaling. This immunocompetent mouse model exhibited increased

susceptibility to *Ot* infection compared to wild-type (WT) B6 mice, as demonstrated by greater

body weight loss, higher clinical disease scores, and elevated bacterial burdens in multiple

organs. Further analysis demonstrated the impaired interferon-stimulated gene expression and

dysregulated innate and adaptive immune cell responses in infected humanized mice. Notably,

intradermal *Ot* infection in humanized mice resulted in eschar-like lesions that closely resemble

those observed in human patients. Together, this humanized and immunocompetent mouse

model, combined with intradermal infection, represents a promising platform for future scrub

typhus studies on bacterial dissemination, immunopathogenesis, and vaccine development.

Materials and Methods

Ethics Statement

UTMB complies with the USDA Animal Welfare Act (Public Law 89–544), Health Research

Extension Act of 1985 (Public Law 99–158), the Public Health Service Policy on Humane Care

and Use of Laboratory Animals, and NAS Guide for the Care and Use of Laboratory Animals

(ISBN-13). UTMB is registered as a Research Facility under the Animal Welfare Act and has

current assurance with the Office of Laboratory Animal Welfare, in compliance with NIH policy.

Infections were performed following Institutional Animal Care and Use Committee approved

protocols (2101001A) at the UTMB in Galveston, TX.

Animals, Infection, and Treatment

Male WT C57BL/6 (#000664) and *Ifngr1$^{-/-}$* (#003288) mice were obtained from the Jackson

Laboratory. Humanized B-hIFNGR1/hIFNG/hIFNGR2 mice (#130949, C57BL/6 background)

were purchased from Biocytogen (Waltham, MA). All mice were maintained under specific

pathogen free conditions and challenged at 11-12 weeks of age. All mouse infection studies were

performed in the ABSL3 facility in the Galveston National Laboratory located at UTMB; all

tissue processing and analysis procedures were performed in the BSL3 or BSL2 facilities. All

procedures were approved by the Institutional Biosafety Committee, in accordance with

Guidelines for Biosafety in Microbiological and Biomedical Laboratories. For infection, mice

were anesthetized using a VetFlo isoflurane vaporizer in an induction chamber. After anesthesia,

the right flank was shaved using an electric trimmer to prepare the injection site. A 20 μL

suspension of the *Ot* Karp strain (3×10^3 FFU in SPG buffer) was injected intradermally into the

right flank using a 0.3 mL insulin syringe with a 31G needle (Sol-Millennium, Chicago, IL).

Mice were monitored for approximately 5 minutes (min) post-injection to ensure full recovery

from anesthesia. Mice were monitored daily for body weight, skin eschar development and

disease severity. At 14 days post-infection (dpi), mice were euthanized by CO_2 inhalation, and

tissues and blood were collected for further analysis.

Bacterial Stock Preparation

Bacteria were inoculated onto L929 murine fibroblast monolayers in T150 cell culture flasks and

gently rocked for two hours (h) at 37°C. After 2 h, Minimum Essential Medium with 10% fetal

bovine serum, 100 units/mL of penicillin and 100 μg/mL of streptomycin were added. Cells were

harvested by scraping at 7 dpi, re-suspended in Minimum Essential Medium, and lysed using 0.5

mm glass beads and vortexing for 1 min. The cell suspension was collected and centrifuged at

$300\times$g for 10 min to pellet cell debris and glass beads. The supernatant from one T150 flask was

further inoculated onto new monolayers of five T150 flasks. This process was repeated for a total

of six passages. Cells from five flasks were pooled in a 50 mL conical tube with 20 mL medium

and 5 mL glass beads. The conical tubes were gently vortexed at 10 sec intervals for 1 min to

release the intracellular bacteria and placed on ice. The tubes were then centrifuged at $300\times$g for

10 min to pellet cell debris, and the supernatant was collected in Oakridge high speed

centrifugation bottles, followed by centrifugation at $22,000\times$g for 45 min at 4°C to harvest

bacteria. Sucrose-phosphate-glutamate buffer (0.218 M sucrose, 3.8 mM KH_2PO_4, 7.2 mM

KH_2PO_4, 4.9 mM monosodium L-glutamic acid, pH 7.0) was used for preparing bacterial stocks,

which were stored at -80°C(24, 35, 36). The same lot of stocks were used for all experiments

described in this study. The titers of the bacterial stocks were measured by focus forming assays,

as previously described(21).

qPCR for Measuring Bacterial Burdens

Bacterial burdens were calculated from collected mouse tissues and cultured cells. The samples

were initially incubated with proteinase K and lysis buffer at 56°C overnight. DNA was

extracted using the DNeasy Blood and Tissue Kit (Qiagen, Germantown, MD) according to the

instructions and used for qPCR assays as previously described(21, 26, 37, 38). The 47-kDa gene

was   amplified   using   the   primer   pair   OtsuF630   (5'-

AACTGATTTTATTCAAACTAATGCTGCT-3')   and   OtsuR747   (5'-

TATGCCTGAGTAAGATACGTGAATGGAATT-3') primers (IDT, Coralville, IA) and

detected   with   the   probe   OtsuPr665   (5'-6FAM-

TGGGTAGCTTTGGTGGACCGATGTTTAATCT-TAMRA) (IDT, Coralville, IA) by

SsoAdvanced Universal Probes Supermix (Bio-Rad, Hercules, CA). Bacterial burdens were

normalized to total microgram (μg) of DNA per μL for the same samples. Absolute

quantification was performed using a 10-fold serial dilution of the *Ot* Karp 47-kDa plasmid

carrying a single copy of the target gene.

Quantitative Reverse Transcriptase PCR (qRT-PCR)

RNA was extracted from mouse lungs and brain using the RNeasy Mini Kit (Qiagen,

Germantown, MD) according to the manufacturer's instruction, followed by the quality and

quantity assessment using a BioTek microplate reader. cDNA was synthesized by using the

iScript Reverse Transcription kit (Bio-Rad, Hercules, CA) with the same amount of RNA (1 μg).

qRT-PCR was performed using 5 μL of iTaq SYBR Green Supermix (Bio-Rad, Hercules, CA), 1

μL of a forward and reverse primer mix (0.5 μM final concentration of each), and 4 μL of diluted

cDNA. Samples were denatured for 30 s at 95°C, followed by 40 cycles of 15 s at 95°C, and 60 s

at 60°C, utilizing a CFX96 Touch real-time PCR detection system (Bio-Rad, Hercules, CA).

Relative quantitation of transcript levels was calculated using the 2−ΔΔCt method and

normalized to glyceraldehyde-4-phosphate dehydrogenase (*Gapdh*). All primers were generated

by Integrated DNA Technologies (IDT, Coralville, IA) and are listed in **S1 Table**. The primer

sequences were obtained from PrimerBank (https://pga.mgh.harvard.edu/primerbank).

Bio-Plex Assay

Whole blood was collected from euthanized mice at 14 dpi, and serum was isolated by using

serum separator tubes (BD Bioscience, San Diego, CA). Bacterial inactivation was performed on

the samples, as described in our previous study(21). The Bio-Plex Pro Mouse Cytokine Th1

Panel was used to measure serum cytokine levels. The Bio-Rad Bio-Plex Plate Washer and Bio-

Plex 200 machine located in the UTMB Flow Cytometry and Cell Sorting Core Lab were used

for sample processing and analysis.

Histology

Tissues were fixed in 10% neutral buffered formalin and embedded in paraffin at the UTMB

Research Histology Service Core. Tissue sections (5-μm thickness) were stained with

hematoxylin and eosin and mounted on slides. Sections were imaged under an Olympus BX53

microscope, and at least five random fields for each section were captured.

Clinical Pathology

Animal blood chemistry analysis was performed by using the VetScan Chemistry Analyzer

(Zoetis, Parsippany-Troy Hills, NJ), according to the manufacturer's instruction. Briefly, mouse

serum (100 μL) was uploaded into the VetScan Comprehensive Diagnostic Profile reagent rotor,

which was used for quantification of alanine aminotransferase (ALT), albumin (ALB), alkaline

phosphatase (ALP), amylase (AMY) total calcium (CA^{++}), globulin (GLOB), glucose (GLU),

phosphorus (PHOS), potassium (K^+), sodium (NA^+), total protein (TP), and urea nitrogen

(BUN). This analysis was performed at the UTMB ABSL3 animal facility.

ELISA

Mouse serum samples were collected and human IFN-γ concentrations were analyzed using the

Legend Max Human IFN-γ ELISA Kit (Biolegend, San Diego, California) according to the

manufacturer's instructions provided by the vendor. To test total IgM and IgG titers in the serum,

96-well plates were precoated with 2 μg/mL of recombinant *Ot* Karp strain TSA56 protein in

PBS and blocked with 0.5% BSA. The recombinant TSA56 protein was generated by Genscript

(Piscataway, NJ). Serum was diluted 1:3 until endpoint titers were determined. Goat anti-mouse

IgM-HRP (1021-05, Southern Biotech) and goat anti-mouse IgG-HRP (1030-05, Southern

Biotech) were used at a 1:3000 dilution for detection. 1-Step Ultra TMB ELISA Substrate

Solution (Thermo Fisher Scientific) was used as the visualizing reagent. Optical density was

measured using a Bio-Tek microplate reader. Area under the curve analysis was performed on

each curve at every timepoint.

Flow Cytometry

Spleen single-cell suspensions were prepared by passing spleen tissues through 70-μm cell

strainers. Red blood cells were removed by using Red Cell Lysis Buffer (Sigma-Aldrich, St.

Louis, MO) for 5 min at RT. For surface marker analysis, leukocytes were stained with the

Fixable Viability Dye (eFluor 506, Thermo Fisher Scientific, Waltham, MA) for live/dead cell

discrimination, blocked with FcγR blocker, and incubated with fluorochrome-labeled antibodies

for 30 min. The fluorochrome-labeled antibodies were purchased from Thermo Fisher Scientific

and Biolegend as below: Alexa Fluor 700 anti-CD11b (M1/70), APC anti-Ly6G (1A8),

PE/Dazzle-594 anti-Ly6C (HK1.4), Percp-Cy5.5 anti-CD11c (N418), FITC anti-MHCII

(M5/114.15.2), PE-Cy7 anti-CD3ε (145-2C11), Percp-cy5.5 anti-CD4 (GK1.5), APC-Cy7-anti-

CD8a (53–6.7), BV711 anti-CD44 (IM7), APC anti-CD62L (MEL-14), PE CF594-anti-NK1.1

(PK136), FITC anti-CD69 (H1.2F3) and Percp-Cy5.5 CTLA4 (UC10-4B9). BV421 anti-F4/80

(T45-2342) antibody was purchased from BD Bioscience (San Diago, CA). For Foxp3 staining,

cells were fixed and permeabilized using Foxp3 / Transcription Factor Fixation/Permeabilization

kit (Thermo Fisher Scientific), followed by the staining with PE anti-Foxp3 (FJK-16s) for 45

min. Cell samples were fixed in 2% paraformaldehyde overnight at 4°C, acquired by a BD

Symphony A5 and analyzed via FlowJo software version 10 (BD, Franklin Lakes, NJ). The

gating strategy of immune cell subsets is based on recent publications(25, 37, 39).

Statistical Analysis

Data are presented as mean ± standard deviation (SD). The data related to qRT-PCR, disease

scores, skin lesion scores, flow cytometry, Bio-Plex and chemistry parameters were analyzed

with one-way ANOVA. Bacterial burdens between two groups were analyzed by the student t-

test. Body weight changes were analyzed by two-way ANOVA. After a significant F-test for the

ANOVA model, either Tukey's multiple comparisons test or Šídák's multiple comparisons test

was used for comparison between groups. All data were analyzed by using GraphPad Prism

software 10. Statistically significant values are denoted as * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$,

and **** $p < 0.0001$, respectively.

Results

Humanized mice are susceptible to *Ot* infection.

Our previous study demonstrated that IFN-γ signaling is essential for host defense against *Ot* infection (25). Given that human IFN-γ signaling may be less robust than its murine counterpart(34), we hypothesized that genetically engineered mice carrying humanized IFN-γ signaling may exhibit increased susceptibility to *Ot* infection. To test this, we utilized a genetically engineered humanized mouse model that possesses functional human IFN-γ signaling while lacking murine IFN-γ signaling. WT and *Ifngr1*[-/-] mice were included as resistant and highly susceptible immunological control models, respectively(25). We chose to use the intradermal infection route, as established in our previous studies(25, 26), to closely mimic the natural mode of *Ot* transmission. As shown in **Figure 1A and B**, WT mice showed marginal body weight changes during infection with low disease scores. However, *Ifngr1*[-/-] mice were of high susceptibility, exhibiting a consistently decreasing body weight and increasing disease scores at 11 and 14 dpi. Humanized mice also showed similar body weight changes and disease scores as *Ifngr1*[-/-] mice until 11 dpi, but these mice started to gain body weight at 12 dpi and continued to recover. By 14 dpi, humanized mice exhibited a comparable disease score as WT mice. Previously, we have shown the first report that *Ifngr1*[-/-] mice, but not WT mice, developed an eschar lesion at the skin inoculation site, which was characterized by necrosis and the formation of a black crust with a red halo, as seen in scrub typhus patients(25). In this study, we observed that humanized mice also formed skin eschar lesions of comparable sizes as *Ifngr1*[-/-] mice at 11 dpi (**Figure 1C and D**). H&E staining of skin tissues in *Ifngr1*[-/-] and humanized mice revealed extensive inflammatory cell infiltration. No eschar lesion and immune cell infiltration

were found in skin samples of uninfected mice at 14 dpi (**S2 Fig**); WT mice exhibited minimal

immune cell infiltration (**Figure 1E**). Therefore, our study provides the first evidence of skin

eschar formation resembling human scrub typhus, and heightened susceptibility to *Ot* infection

using an immunocompetent humanized mouse model.

Systemic inflammation in humanized mice following *Ot* infection.

To assess whether *Ot* infection induces inflammatory responses in major organs of humanized

mice, we performed histological analyses on the liver, lung, and brain tissues at 14 dpi (**Figure**

2). In uninfected WT and humanized mice, no notable immune cell infiltration was detected in

the liver. Following *Ot* infection, WT mice showed mild inflammatory cell infiltration limited to

the portal triads, with minimal involvement of the lobular regions. In contrast, humanized mice

exhibited moderate portal inflammation accompanied by inflammatory cell infiltration extending

into the lobular areas. No tissue necrosis was observed in any samples. For the lung tissues,

uninfected samples saw intact alveolar architecture, accompanied by minimal or no cellular

infiltration. The lung histology of infected humanized mice revealed increased mononuclear cell

infiltration throughout the interstitium compared to infected WT mice, suggesting moderate

interstitial pneumonitis in infected humanized mice. It is known that *Ot* infection can cause

blood brain barrier disruption and central nervous system disorders(35, 40, 41). We also found

that the meningeal layer of humanized mice with *Ot* infection showed clear mononuclear cell

infiltration, indicating meningitis or meningoencephalitis. Overall, our data demonstrated

systemic inflammation across multiple organs in the humanized mouse model of scrub typhus.

***Ot* infection induces human, but not murine IFN-γ signaling in humanized mice**

To confirm the activation of human IFN-γ signaling in humanized mice following infection, we

measured the transcript levels of *Ifngr1* and *Ifngr2* in brain and lung tissues, which are the

primary *Ot* target organs for severe disease outcomes(42). As shown in **Figure 3A** and **B**, WT

mice expressed mouse, but not human *Ifngr1* and *Ifngr2* in both the brain and lungs, while

humanized mice only expressed human but not mouse *Ifngr1* and *Ifngr2*. We further quantified

human IFN-γ protein levels in sera by using specific ELISA. We found that human IFN-γ levels

in the serum were minimal in uninfected humanized mice but increased significantly after

infection (**Figure 3C**), and that human IFN-γ was undetectable in uninfected or infected WT

mice. Altogether, our results demonstrated that humanized mice activate human but not mouse

IFN-γ responses after *Ot* infection.

Serum cytokines and biochemical profiles in humanized mice with *Ot* infection.

To better understand the status of systemic immune responses, we analyzed serum cytokines of

WT and humanized mice by Bio-Plex assay. Reinforcing the RT-qPCR data of **Figure 3**, the

Bio-Plex assay showed that mouse IFN-γ was significantly upregulated in infected WT mice, but

it was undetected in humanized mice (**Figure 4**). A general trend of cytokine upregulation was

observed in both WT and humanized mice following infection, with increased levels of IL1β, IL-

2, IL-10 and IL-6. Of these, serum IL-6 was significantly elevated in infected-humanized mice

when compared to WT controls, suggesting a heightened IL-6-mediated inflammatory response

in the humanized mouse model.

To evaluate animal physiological status, we measured serum biochemical parameters by using

VetScan Comprehensive Diagnostic Profile reagent rotors. In the absence of infection,

humanized mice showed no physiological abnormalities, as indicated by serum biochemical

parameters comparable to those of WT mice. (**Figure 4B**). However, *Ot* infection resulted in

significantly decreased levels of alkaline phosphatase (ALP), albumin (ALB), and glucose

(GLU), with more pronounced reductions observed in humanized mice. Amylase (AMY) levels

showed a significantly increased trend in WT mice after infection, whereas a more pronounced

decrease was observed in humanized mice, consistent with findings in *Ifngr1*□/□ mice(25).

These results may suggest compromised liver function and malnutrition in humanized mice. This

pattern of biochemical changes closely aligns with our previous observations in *Ifngr1*-deficient

mice(25). In addition, a further increase of globulin (GLOB) in humanized mice may indicate

heightened inflammation in response to infection. Both WT and humanized infected mice

demonstrated a dysregulation of total protein (TP), alanine aminotransferase (ALT), phosphorus

(PHOS) and potassium (K+). These findings suggest an enhanced systemic inflammatory

response and disrupted physiological homeostasis in humanized mice following *Ot* infection.

To assess whether humanized mice exhibit altered humoral immunity in response to *Ot* infection,

we measured *Ot*-specific antibody titers in mouse sera. ELISA results showed comparable levels

of IgM and IgG against *Ot* TSA56 antigen between humanized and WT mice (**S3 Fig**), indicating

that humanized mice mount a competent humoral immune response like WT controls.

Elevated bacterial burden but reduced interferon-stimulated gene (ISG) expression in

humanized mice

To assess bacterial control in humanized mice, bacterial burdens were measured in various

organs (**Figure 5A**). Consistent with previous findings(22, 25), the highest bacterial burden was

observed in mouse lungs, followed by the spleens in both WT and humanized mice. We found

that humanized mice exhibited approximately a 2-fold increase in bacterial burden in the lungs

and spleen. Notably, a 10-fold increase of bacterial burdens in the brain was detected in

humanized mice as compared to WT mice. Likewise, the kidney and liver organs in humanized

mice also showed significantly higher bacterial burden. These results suggest that human IFN-γ

signaling confers weaker antibacterial activity compared to its murine counterpart.

IFN-γ signaling activates the JAK-STAT pathway and induces the expression of multiple

downstream ISGs, driving a robust antibacterial response(43). Disruption of IFN-γ/STAT1

signaling has been shown to result in uncontrolled bacterial replication and lethal *Ot*

infection(25). To assess the antibacterial response of the humanized scrub typhus model, we

examined ISG transcript levels in various organs by qRT-PCR. Our results demonstrated that as

compared to WT mice, humanized mice showed lower expression of all examined ISGs in the

brain, including *Cxcl10*, *Nos2*, *Ifit1/2*, *Gbp2/4/5*, *Isg15*, *Isg20*, *Stat1*, *Rsad2*, *Oas3*, *Oas1b* and

Oasl2 (**Figure 5B**). Furthermore, we confirmed that the lungs of humanized mice also exhibited

lower expression of some ISGs including *Cxcl10*, *STAT1*, *Ifit1/2*, *Rsad2*, *Isg15,* and *Oasl2* (**S4**

Fig). In addition, the inflammatory cytokine levels (*IL6*, *Tnf* and *Il27)* were comparable in both

lungs and brain between two groups (**Figure 5B and S4 Fig**). Interestingly, we found that

humanized mice expressed significantly higher levels of *Sele* (E-selectin) and *Selp* (P-selectin) in

the brain, but not in the lungs, indicating increased endothelial activation and inflammation in the

brain of humanized mice with *Ot* infection.

Dysregulated innate and adaptive immune cell response in humanized mice following *Ot* infection

Ot infection triggers robust innate and adaptive immune responses, characterized by strong type 1 immunity and activation of multiple immune cell subsets, including NK cells, macrophages, dendritic cells, neutrophils, and effector T cells. While these cells play critical roles in controlling bacterial replication and dissemination, their excessive activation can lead to immunopathogenesis. We found that *Ot* infection induced stronger CD4$^+$ and CD8$^+$ T effector cell responses in the spleens of humanized mice compared to WT controls (**Figure 6A**). However, there was a significantly decreased percentage of Treg cells among CD4$^+$ T cells (**Figure 6B**). Moreover, CTLA4□ Treg cell numbers were markedly reduced in humanized mouse spleens (**Figure 6C**). This result suggests that *Ot* infection leads to excessive T cell activation accompanied by a diminished immunosuppressive T cell response in humanized mice.

Excessive neutrophil response and limited innate immune cell activation in humanized mice

Neutrophilia is observed in scrub typhus patients and is linked to disease progress(44, 45). We found that infected humanized mice exhibited 3.4-fold higher neutrophil numbers in the spleen as compared to WT controls (**Figure 7A**). Monocytes were also recruited into the spleen following infection, with comparable infiltration levels observed between WT and humanized mice (**Figure 7B**). Notably, both macrophages and dendritic cells in infected humanized mice exhibited reduced MHC II expression, indicating impaired activation of antigen-presenting cells in response to human IFN-γ signaling. Humanized mice also harbored significantly fewer NK cells, which displayed a markedly lower activation status, as evidenced by reduced CD69

expression (**Figure 7C**). Overall, our results suggest an increased neutrophil response alongside

impaired activation of other innate immune cells in humanized mice of *Ot* infection.

Discussion

Scrub typhus is a systemic, life-threatening disease with a high incidence in the "tsutsugamushi

triangle", yet it remains significantly neglected(46). A better understanding of *Ot* pathogenesis

and the development of effective vaccines represent the most promising strategies for preventing

future outbreaks of this disease(47, 48). Although several animal models have been established

by other researchers and our group(14-19, 21, 22, 28, 49, 50), there remains a need for an

accurate mouse model that closely recapitulates human scrub typhus. In this study, we introduce

a newly developed genetically engineered humanized mouse model for scrub typhus, featuring

functional human IFN-γ signaling in the absence of murine IFN-γ signaling. We demonstrated

that this humanized mouse strain exhibits increased susceptibility to intradermal *Ot* infection,

characterized by multiorgan bacterial dissemination, skin eschar formation, systemic

inflammation, altered serum biochemical profiles, and dysregulated innate and adaptive immune

responses. This study represents the first establishment of a scrub typhus model using genetically

engineered humanized mice, and our findings support the utility of this model as a promising

tool for future studies on pathogenesis, drug screening, and vaccine development.

We have previously demonstrated that IFN-γ signaling is necessary for host defense against *Ot*

infection as the *Ifngr1$^{-/-}$* mouse strain, in contrast to WT B6 mice, develops a lethal model of

scrub typhus and forms a skin eschar lesion at the site of intradermal inoculation(25). The eschar

serves as a key diagnostic indicator in patients with acute febrile illness in regions endemic for

442 scrub typhus(51-53). Clinical observation indicates that the presence of an eschar might be

443 associated with increased disease severity(54, 55). Our study reports skin eschar lesions in an

444 immunocompetent mouse model in response to *Ot* infection for the first time. Representative HE

445 staining of eschar lesions show apparent immune infiltration in both humanized and *Ifngr1*$^{-/-}$

446 mice, but not in WT mice (Figure 1E). Therefore, our data generated from our humanized mouse

447 model (Figure 1), along with the previously published *Ifngr1*$^{-/-}$ model(25) suggest that the

448 species-specific differences in IFN-γ signaling might be a critical determinant of eschar

449 formation and disease severity of scrub typhus. The downstream mechanisms by which IFN-γ

450 signaling influences eschar formation, however, still remain unclear. Interestingly, unlike mouse

451 cells that express strong inducible nitric oxide synthase (iNOS) by IFN-γ stimulation, human

452 cells instead produce indoleamine dioxygenase (34). Due to the key role of iNOS in wound

453 healing(56), it is possible that compromised IFN-γ/iNOS signaling contributes to eschar

454 formation in not only scrub typhus, but also rickettsial infection(57). Further studies are needed

455 to elucidate downstream mechanisms by which IFN-γ signaling influences eschar formation.

457 Scrub typhus can cause systemic infection and multiorgan dysfunction, particularly in cases with

458 delayed diagnosis and treatment. Immune infiltration in response to infection leads to

459 inflammatory damage and organ failure in patients(52, 58-60). Our histology assessment, serum

460 Bio-plex assay, biochemical analysis and bacterial burden measurement collectively demonstrate

461 systemic bacterial dissemination and inflammatory responses across multiple organs, including

462 lung, liver and brain in the humanized mouse model (Figure 2, 4 and 5). The immune and

463 biochemical profiles in humanized mice revealed unique features consistent with those observed

464 in our recently published *Ifngr1*$^{-/-}$ mouse model(25). For example, serum analysis revealed

elevated IL-6 in humanized mice compared to WT mice following infection, a characteristic that

is also noted in scrub typhus patients (61, 62). Similar IL-6 upregulation was also observed in

Ifngr1[-/-] mice infected with *Ot*(25), indicating that the proinflammatory cytokine IL-6 may serve

as a potential biomarker for predicting disease severity in scrub typhus. In addition, the

decreased serum levels of ALP, ALB and GLU which were found in infected *Ifngr1*[-/-] mice(25),

were also observed in humanized mice compared to WT controls (Figure 4), indicating excessive

liver dysfunction in this novel mouse model. Therefore, combining serum cytokine profiles and

biochemical parameters with bacterial load may offer a more accurate prediction of disease

severity in scrub typhus patients.

Scrub typhus has become a leading cause of central nervous system infection in endemic

regions(63, 64). Severe infection can lead to a range of neurological complications, including

meningitis, encephalitis, and meningoencephalitis, which are associated with increased

mortality(35, 41, 65-68). Moreover, *Ot* infection may increase the risk of long-term sequelae and

neurodegenerative diseases, such as dementia(69, 70). In this study, the increased susceptibility

of humanized mice to *Ot* infection is evidenced by higher bacterial burdens in multiple organs

compared to WT mice (Figure 5A). Notably, brain tissues of humanized mice exhibited the most

pronounced increase, with bacterial burdens approximately 10-fold higher than those in WT

controls. The uncontrolled bacterial replication observed in the brain may be attributed to the

substantial downregulation of several ISGs (Figure 5B). Consistent with this, histological

analysis also showed significant immune cell infiltration within the brain meninges of humanized

mice, which may contribute to meningoencephalitis (Figure 2). The significantly elevated

expression of key adhesion molecules *Sele* (E-selectin) and *Selp* (P-selectin) in the brains of

humanized mice may indicate robust neuroinflammation and potential blood-brain barrier

dysfunction(71-73). These findings may support the utility of the humanized mouse model as a

valuable tool for investigating neurological complications associated with scrub typhus.

We further evaluated innate and adaptive immune responses in humanized mice following

infection (Figure 5-7, S2 Fig and S3 Fig). Activation of IFN signaling induces robust expression

of ISGs, which play a critical role in controlling pathogen replication(74-76). Thus, we first

analyzed a comprehensive ISG expression panel in both the brain and lungs. We found that the

expression of several ISGs (*Ifit1*, *Ifit2, Rsad2, Isg15, Cxcl10* and *Oasl2*) were downregulated in

both organs of humanized mice, whereas members of the *Gbp* family (*Gbp2*, *Gbp4* and *Gbp5*),

were selectively reduced in the brain. Given that bacterial burdens in humanized mice were

approximately 10-fold higher in the brain and only 2.5-fold higher in the lungs compared to WT

mice (Figure 5A), these findings suggest that distinct ISGs may contribute differentially to

bacterial control in an organ specific manner. Next, we used flow cytometry to profile innate and

adaptive immune cell populations in the spleens. We observed an imbalance between effector

and regulatory T cells in humanized mice, characterized by an increase in activated effector T

cells and a reduction in Treg cells (Figure 6). This imbalance might be due to the impaired

bacterial clearance and may lead to heightened systemic inflammation. It is known that IFN

signaling is critical for antigen-presenting cell maturation and NK cell activation(77-80). Our

data showed that humanized IFN-γ signaling led to a significant reduction in MHC class II

expression on antigen-presenting cells and impaired activation of NK cells (Figure 7). This

finding reveals a potential underlying mechanism for the greater susceptibility of humans to *Ot*

infection compared to mice. Neutrophilia is a common feature of acute scrub typhus(44) and

increased neutrophil activation has been associated with disease progression(45). Consistent with

these clinical observations, we found that neutrophil populations were more than 3-fold higher in

humanized mice compared to WT mice following infection (Figure 7), suggesting that this

humanized mouse model recapitulates key aspects of immune dysregulation observed in patients

with acute scrub typhus. Lastly, we measured the *Ot*-specific antibody titers in mouse serum and

found that humanized mice produced IgM and IgG comparable to those of WT controls (S3 Fig).

The intact antibody response supports the suitability of this animal model for future vaccine

studies.

Humanized mouse models represent promising tools for studying scrub typhus. Jiang et al. found

that humanized DRAGA mice were highly susceptible to intradermal and subcutaneous

infection, mounted strong CD4$^+$ and cytotoxic T cell responses, and produced human IgM and

IgG following repeated immunization, suggesting it as a new pre-clinical model for *Ot*

pathogenesis study and vaccine candidate testing(50). Our study using mice with humanized

IFN-γ signaling builds on our recent findings that IFN-γ, rather than type I interferons, plays a

critical role in skin eschar formation and host defense against *Ot* infection(25). To our

knowledge, this triple KO/KI mouse model has never been applied in any research study so far.

Although the vendor validated the genetic manipulation, downstream signaling activation, and

immune cell profiles, we further confirmed the expression of IFN-γ and its receptors in both

humanized and WT mice during infection (Figure 3). A limitation of our study is the limited

number of animals available, which restricted our ability to comprehensively assess the temporal

dynamics of susceptibility, pathology, and immune responses. Since our model is a genetically

engineered humanized mouse strain, it should not be confused with cellular humanization, where

mice are engrafted with human cells such as hematopoietic stem cells or peripheral blood

mononuclear cells. Moreover, these germline-modified mice can be bred, making them a more

cost-effective and time-efficient option for experimental studies.

In sum, we reported a novel humanized mouse model that is susceptible to *Ot* infection and

forms skin eschars via an intradermal infection route, effectively replicating human scrub typhus

disease. Future investigations are warranted by using this novel model to evaluate bacterial

virulence, characterize host protective immunity and assess the efficacy of potential new vaccine

candidates.

Acknowledgements

We would like to thank the UTMB Flow Cytometry and Cell Sorting Core Lab (Meredith

Weglarz) and Dr. Joseph Jelinski for sample analysis and manuscript revision, respectively.

Figure Legends

Figure 1. Humanized mice are susceptible to *Ot* infection. WT B6 (n=6), *Ifngr1*$^{-/-}$ (n=4) and

humanized (n=4) mice were intradermally infected with *Ot* (3×10^3 FFU) on the right flank. Mice

were monitored daily for (A) body weight changes and (B) disease scores. (C) Skin eschar

lesions at inoculation sites at 11 dpi are presented and (D) their sizes are measured. (E)

Representative histological images of the skin eschar lesion are shown at 11 dpi. Scale bar = 100

µm. Data are presented as mean ± SD from two independent pooled experiments. Body weight

changes were analyzed by two-way ANOVA with Tukey's multiple comparisons between WT

and humanized mice at indicated time points. Disease scores (11 and 14 dpi) and skin eschar

lesion size (11 dpi) were analyzed by one-way ANOVA with Tukey's multiple comparisons.

*, $p < 0.05$; **, $p < 0.01$; ***, $p < 0.001$; ****, $p < 0.0001$.

Figure 2. Tissue histology of WT, *Ifngr1*^-/- and humanized mice following *Ot* infection. WT

B6 (n=9) and humanized (n=6) mice were infected as described in Figure 1. Uninfected WT B6

(n=3) and humanized (n=2) were i.d. injected with L929 cell culture control. Representative

histological images of the liver, lung and brain are shown at 14 dpi. Scale bar = 100 µm.

Figure 3. Expression of *Ifng*, *Ifngr1* and *Ifngr2* in WT and humanized mice. Mice were

infected as described in Figure 2. (A-B) RNA was extracted from mouse brain and lung tissues.

Mouse and human *Ifngr1* and *Ifngr2* transcript levels were analyzed by RT-qPCR, and the

relative fold changes are shown. (C) Human IFN-γ levels in the sera of WT B6 and humanized

mice were measured by sandwich ELISA. The label "u.d." represents undetectable levels. Data

are presented as mean ± SD from three independent pooled experiments.

Figure 4. Serum cytokines and chemistry profiles in humanized mice with *Ot* infection.

Mice were infected as described in Figure 1. (A) Serum cytokine and chemokine levels were

analyzed at 14 dpi by a Bio-Plex assay. (B) The serum chemistry parameters were detected by

using VetScan Comprehensive Diagnostic Profile Reagent Rotor. The parameters include alanine

aminotransferase (ALT), albumin (ALB), alkaline phosphatase (ALP), amylase (AMY), total

calcium (CA^{++}), globulin (GLOB), glucose (GLU), potassium (K^+), sodium (NA^+), total protein

(TP), blood urea nitrogen (BUN), and phosphorus (PHOS). Data are shown as mean ± SD from

three pooled independent experiments and analyzed by one-way ANOVA with a Tukey's

multiple comparisons test. *, $p < 0.05$; **, $p < 0.01$; ***, $p < 0.001$; ****, $p < 0.0001$.

Figure 5. Humanized mice exhibited an increased bacterial burden and reduced expression

of interferon stimulated genes (ISGs) following *Ot* infection. Mice were infected as described

in Figure 1 and were euthanized at 14 dpi. (A) Genomic DNA was isolated from the lung,

spleen, brain, kidney and liver. Bacterial burden was measured by qPCR. (B) The transcript

levels of ISGs in the brain were analyzed by qRT-PCR. Data are shown as mean ± SD from three

pooled independent experiments and analyzed by unpaired t-test for bacterial burdens and one-

way ANOVA with a Šídák's multiple comparisons test for ISG expression. *, $p < 0.05$; **, $p <$

0.01; ***, $p < 0.001$; ****, $p < 0.0001$; ns, no significant difference.

Figure 6. Imbalanced T cell responses in humanized mice following infection. Mice were

infected as described in Figure 1 and were euthanized at 14 dpi. Spleen cells were isolated and

analyzed by flow cytometry. Single cells were gated first by FSC/SSC, followed by the exclusion

of dead cells by live/dead staining. (A-B) $CD4^+$ and $CD8^+$ T cells were gated on $CD3^+CD4^+$ and

$CD3^+CD8^+$, respectively. $CD44^+CD62L^-$ T cells were identified as activated populations. (C) For

regulatory T (Treg) cells, Foxp3 was gated on $CD4^+$ T cells and the expression of CTLA4 was

further gated on $CD4^+Foxp3^+$ T cells. The percentages of cell populations were shown as mean ±

SD on the flow cytometric images and the statistical analysis between infected WT and

humanized mice were labeled. The absolute numbers of cell populations were also calculated and

shown next to the flow cytometric images. One-way ANOVA with a Šídák's multiple

comparisons test was used for data analysis. *, $p < 0.05$; **, $p < 0.01$; ***, $p < 0.001$; ****, $p <$

0.0001.

Figure 7. Excessive neutrophils and reduced innate immune cell activation in humanized

mice following *Ot* infection. Mice were infected as described in Figure 1 and were euthanized at

14 dpi. Spleen cells were isolated and analyzed by flow cytometry. Single cells were gated first

by FSC/SSC, followed by the exclusion of dead cells by live/dead staining. (A-B) Neutrophils

and monocytes were identified by $CD11^+Ly6G^+$ and $CD11b^+Ly6C^{hi}$, respectively. $CD11b^+Ly6C^-$

cells were further gated by CD11c and F4/80 markers. Macrophages and dendritic cells were

characterized by $CD11c^-F4/80^+$ and $CD11c^{hi}F4/80^+$, respectively. The mean fluorescent intensity

(MFI) of MHCII on macrophages and dendritic cells were measured. (C) NK cells were gated on

$CD3^-NK1.1^+$, and CD69 was used as an activation marker of NK cells. The percentages of cell

populations were shown as mean ± SD on the flow cytometric images and the statistical analysis

between infected WT and humanized mice were labeled. The absolute numbers and MFI of cell

populations were also calculated and were shown next to the flow cytometric images. One-way

ANOVA with a Šídák's multiple comparisons was used for data analysis. *, $p < 0.05$; **, $p <$

0.01; ***, $p < 0.001$; ****, $p < 0.0001$.

S1 Table. Sequences of PCR primers. All primer sequences are obtained from PrimerBank

(https://pga.mgh.harvard.edu/primerbank/) or our previous publications.

S2 Fig. Skin histology of uninfected mice.

Skin tissues from uninfected WT and humanized mice were collected and subjected to H&E

staining. Representative histological images are shown at 14 dpi. Scale bar = 100 µm.

S3 Fig. Comparable *Ot*-specific IgM and IgG levels in humanized and WT control mice. To

measure relative amounts of IgM and IgG antibodies, mouse sera were collected at 14 dpi as

shown in Figure 1 and then diluted to create a dilution curve. Uninfected mouse sera were used

as controls. The area under the curve (AUC) is calculated from three pooled independent

experiments and shown as mean ± SD. One-way ANOVA with a Šídák's multiple comparisons

was used for data analysis. *, $p < 0.05$; **, $p < 0.01$.

S4 Fig. Reduced expression of ISGs in the lungs of humanized mice with *Ot* infection. Mice

were infected as described in Figure 1 and were euthanized at 14 dpi. The transcript levels of

ISGs and inflammatory genes in the lungs were analyzed by qRT-PCR. Data are shown as mean

± SD from three pooled independent experiments and analyzed by one-way ANOVA with a

Šídák's multiple comparisons test. *, $p < 0.05$; **, $p < 0.01$; ***, $p < 0.001$.

References

1.   Xu G, Walker DH, Jupiter D, Melby PC, Arcari CM. A review of the global

epidemiology of scrub typhus. PLoS Negl Trop Dis. 2017;11(11):e0006062.

2.   Luce-Fedrow A, Lehman ML, Kelly DJ, Mullins K, Maina AN, Stewart RL, et al. A

Review of Scrub Typhus (*Orientia tsutsugamushi* and Related Organisms): Then, Now, and

Tomorrow. Trop Med Infect Dis. 2018;3(1):8.

3.   Shin EH, Roh JY, Park WI, Song BG, Chang KS, Lee WG, et al. Transovarial

transmission of *Orientia tsutsugamushi* in Leptotrombidium palpale (Acari: Trombiculidae).

PLoS One. 2014;9(4):e88453.

4.   Venkategowda PM, Rao SM, Mutkule DP, Rao MV, Taggu AN. Scrub typhus: Clinical

spectrum and outcome. Indian J Crit Care Med. 2015;19(4):208-13.

5.   Jeong YJ, Kim S, Wook YD, Lee JW, Kim KI, Lee SH. Scrub typhus: clinical,

pathologic, and imaging findings. Radiographics. 2007;27(1):161-72.

6.   Taylor AJ, Paris DH, Newton PN. A Systematic Review of Mortality from Untreated

Scrub Typhus (*Orientia tsutsugamushi*). PLoS Negl Trop Dis. 2015;9(8):e0003971.

7.   Peter JV, Sudarsan TI, Prakash JA, Varghese GM. Severe scrub typhus infection: Clinical

features, diagnostic challenges and management. World J Crit Care Med. 2015;4(3):244-50.

8.   Pai H, Sohn S, Seong Y, Kee S, Chang WH, Choe KW. Central nervous system

involvement in patients with scrub typhus. Clin Infect Dis. 1997;24(3):436-40.

9.   Kim DM, Kim SW, Choi SH, Yun NR. Clinical and laboratory findings associated with

severe scrub typhus. BMC Infect Dis. 2010;10:108.

10.   Jiang J, Richards AL. Scrub Typhus: No Longer Restricted to the Tsutsugamushi

Triangle. Trop Med Infect Dis. 2018;3(1):11.

11.   Chen K, Travanty NV, Garshong R, Crossley D, Wasserberg G, Apperson CS, et al.

Detection of *Orientia* spp. Bacteria in Field-Collected Free-Living *Eutrombicula* Chigger Mites,

United States. Emerg Infect Dis. 2023;29(8):1676-9.

12.   Chaichana P, Satapoomin N, Kullapanich C, Chuenklin S, Mohammad A, Inthawong M,

et al. Comparative virulence analysis of seven diverse strains of *Orientia tsutsugamushi* reveals a

multifaceted and complex interplay of virulence factors responsible for disease. PLoS Pathog.

2025;21(6):e1012833.

13.   Walker DH, Mendell NL. A scrub typhus vaccine presents a challenging unmet need.

NPJ Vaccines. 2023;8(1):11.

14.   Mendell NL, Xu G, Shelite TR, Bouyer DH, Walker DH. A Murine Model of Waning

Scrub Typhus Cross-Protection between Heterologous Strains of *Orientia tsutsugamushi*.

Pathogens. 2022;11(5):512.

15.   Luce-Fedrow A, Chattopadhyay S, Chan TC, Pearson G, Patton JB, Richards AL.

Comparison of Lethal and Nonlethal Mouse Models of *Orientia tsutsugamushi* Infection Reveals

T-Cell Population-Associated Cytokine Signatures Correlated with Lethality and Protection.

Trop Med Infect Dis. 2021;6(3):121.

16.   Linsuwanon P, Wongwairot S, Auysawasdi N, Monkanna T, Richards AL, Leepitakrat S,

et al. Establishment of a Rhesus Macaque Model for Scrub Typhus Transmission: Pilot Study to

Evaluate the Minimal *Orientia tsutsugamushi* Transmission Time by Leptotrombidium

chiangraiensis Chiggers. Pathogens. 2021;10(8):1028.

17.   Sunyakumthorn P, Somponpun SJ, Im-Erbsin R, Anantatat T, Jenjaroen K, Dunachie SJ,

et al. Characterization of the rhesus macaque (Macaca mulatta) scrub typhus model:

Susceptibility to intradermal challenge with the human pathogen *Orientia tsutsugamushi* Karp.

PLoS Negl Trop Dis. 2018;12(3):e0006305.

18.   Mendell NL, Bouyer DH, Walker DH. Murine models of scrub typhus associated with

host control of *Orientia tsutsugamushi* infection. PLoS Negl Trop Dis. 2017;11(3):e0005453.

19.   Soong L, Mendell NL, Olano JP, Rockx-Brouwer D, Xu G, Goez-Rivillas Y, et al. An

Intradermal Inoculation Mouse Model for Immunological Investigations of Acute Scrub Typhus

and Persistent Infection. PLoS Negl Trop Dis. 2016;10(8):e0004884.

20.   Paris DH, Chattopadhyay S, Jiang J, Nawtaisong P, Lee JS, Tan E, et al. A nonhuman

primate scrub typhus model: protective immune responses induced by pKarp47 DNA

vaccination in cynomolgus macaques. J Immunol. 2015;194(4):1702-16.

21.   Shelite TR, Saito TB, Mendell NL, Gong B, Xu G, Soong L, et al. Hematogenously

disseminated *Orientia tsutsugamushi*-infected murine model of scrub typhus [corrected]. PLoS

Negl Trop Dis. 2014;8(7):e2966.

22.   Keller CA, Hauptmann M, Kolbaum J, Gharaibeh M, Neumann M, Glatzel M, et al.

Dissemination of *Orientia tsutsugamushi* and inflammatory responses in a murine model of

scrub typhus. PLoS Negl Trop Dis. 2014;8(8):e3064.

23.   Ewing EP, Jr., Takeuchi A, Shirai A, Osterman JV. Experimental infection of mouse

peritoneal mesothelium with scrub typhus rickettsiae: an ultrastructural study. Infect Immun.

1978;19(3):1068-75.

24.   Thiriot JD, Liang Y, Gonzales C, Sun J, Yu X, Soong L. Differential cellular immune

responses against *Orientia tsutsugamushi* Karp and Gilliam strains following acute infection in

mice. PLoS Negl Trop Dis. 2023;17(12):e0011445.

25.   Liang Y, Wang H, Sun K, Sun J, Soong L. Lack of the IFN-gamma signal leads to lethal

Orientia tsutsugamushi infection in mice with skin eschar lesions. PLoS Pathog.

2024;20(5):e1012020.

26.   Liang Y, Wang H, Gonzales C, Thiriot J, Sunyakumthorn P, Melby PC, et al.

CCR7/dendritic cell axis mediates early bacterial dissemination in *Orientia tsutsugamushi*-

infected mice. Front Immunol. 2022;13:1061031.

27.   Petermann M, Orfanos Z, Sellau J, Gharaibeh M, Lotter H, Fleischer B, et al. CCR2

Deficiency Impairs Ly6C(lo) and Ly6C(hi) Monocyte Responses in *Orientia tsutsugamushi*

Infection. Front Immunol. 2021;12:670219.

28.   Sunyakumthorn P, Paris DH, Chan TC, Jones M, Luce-Fedrow A, Chattopadhyay S, et

al. An intradermal inoculation model of scrub typhus in Swiss CD-1 mice demonstrates more

rapid dissemination of virulent strains of *Orientia tsutsugamushi*. PLoS One. 2013;8(1):e54570.

29.   Munch CC, Upadhaya BP, Rayamajhee B, Adhikari A, Munch M, En-Nosse N, et al.

Multiple *Orientia* clusters and Th1-skewed chemokine profile: a cross-sectional study in patients

with scrub typhus from Nepal. Int J Infect Dis. 2023;128:78-87.

30.   Inthawong M, Sunyakumthorn P, Wongwairot S, Anantatat T, Dunachie SJ, Im-Erbsin R,

et al. A time-course comparative clinical and immune response evaluation study between the

human pathogenic *Orientia tsutsugamushi* strains: Karp and Gilliam in a rhesus macaque

(Macaca mulatta) model. PLoS Negl Trop Dis. 2022;16(8):e0010611.

31.   Fisher J, Card G, Liang Y, Trent B, Rosenzweig H, Soong L. *Orientia tsutsugamushi*

selectively stimulates the C-type lectin receptor Mincle and type 1-skewed proinflammatory

immune responses. PLoS Pathog. 2021;17(7):e1009782.

32.   Soong L, Wang H, Shelite TR, Liang Y, Mendell NL, Sun J, et al. Strong type 1, but

impaired type 2, immune responses contribute to *Orientia tsutsugamushi*-induced pathology in

mice. PLoS Negl Trop Dis. 2014;8(9):e3191.

33.   Schroder K, Hertzog PJ, Ravasi T, Hume DA. Interferon-gamma: an overview of signals,

mechanisms and functions. J Leukoc Biol. 2004;75(2):163-89.

34.   Roshick C, Wood H, Caldwell HD, McClarty G. Comparison of gamma interferon-

mediated antichlamydial defense mechanisms in human and mouse cells. Infect Immun.

2006;74(1):225-38.

35.   Liang Y, Aditi, Onyoni F, Wang H, Gonzales C, Sunyakumthorn P, et al. Brain

transcriptomics reveal the activation of neuroinflammation pathways during acute *Orientia*

tsutsugamushi infection in mice. Front Immunol. 2023;14:1194881.

36.   Giengkam S, Blakes A, Utsahajit P, Chaemchuen S, Atwal S, Blacksell SD, et al.

Improved Quantification, Propagation, Purification and Storage of the Obligate Intracellular

Human Pathogen *Orientia tsutsugamushi*. PLoS Negl Trop Dis. 2015;9(8):e0004009.

37.   Liang Y, Fisher J, Gonzales C, Trent B, Card G, Sun J, et al. Distinct Role of TNFR1 and

TNFR2 in Protective Immunity Against *Orientia tsutsugamushi* Infection in Mice. Front

Immunol. 2022;13:867924.

38.   Trent B, Liang Y, Xing Y, Esqueda M, Wei Y, Cho NH, et al. Polarized lung

inflammation and Tie2/angiopoietin-mediated endothelial dysfunction during severe *Orientia*

tsutsugamushi infection. PLoS Negl Trop Dis. 2020;14(3):e0007675.

39.   Gonzales C, Liang Y, Fisher J, Card G, Sun J, Soong L. Alterations in germinal center

formation and B cell activation during severe *Orientia tsutsugamushi* infection in mice. PLoS

Negl Trop Dis. 2023;17(5):e0011090.

40.   Dittrich S, Sunyakumthorn P, Rattanavong S, Phetsouvanh R, Panyanivong P,

Sengduangphachanh A, et al. Blood-Brain Barrier Function and Biomarkers of Central Nervous

System Injury in Rickettsial Versus Other Neurological Infections in Laos. Am J Trop Med Hyg. 2015;93(2):232-7.

41.   Alam AM, Gillespie CS, Goodall J, Damodar T, Turtle L, Vasanthapuram R, et al. Neurological manifestations of scrub typhus infection: A systematic review and meta-analysis of clinical features and case fatality. PLoS Negl Trop Dis. 2022;16(11):e0010952.

42.   Moron CG, Popov VL, Feng HM, Wear D, Walker DH. Identification of the target cells of *Orientia tsutsugamushi* in human cases of scrub typhus. Mod Pathol. 2001;14(8):752-9.

43.   Platanias LC. Mechanisms of type-I- and type-II-interferon-mediated signalling. Nat Rev Immunol. 2005;5(5):375-86.

44.   Cho BA, Ko Y, Kim YS, Kim S, Choi MS, Kim IS, et al. Phenotypic characterization of peripheral T cells and their dynamics in scrub typhus patients. PLoS Negl Trop Dis. 2012;6(8):e1789.

45.   Paris DH, Stephan F, Bulder I, Wouters D, van der Poll T, Newton PN, et al. Increased Nucleosomes and Neutrophil Activation Link to Disease Progression in Patients with Scrub Typhus but Not Murine Typhus in Laos. PLoS Negl Trop Dis. 2015;9(8):e0003990.

46.   Walker DH. Scrub Typhus - Scientific Neglect, Ever-Widening Impact. N Engl J Med. 2016;375(10):913-5.

47.   Banerjee A, Kulkarni S. *Orientia tsutsugamushi*: The dangerous yet neglected foe from the East. Int J Med Microbiol. 2021;311(1):151467.

48.   Valbuena G, Walker DH. Approaches to vaccines against *Orientia tsutsugamushi*. Front Cell Infect Microbiol. 2012;2:170.

49.   Thiriot J, Liang Y, Fisher J, Walker DH, Soong L. Host transcriptomic profiling of CD-1

outbred mice with severe clinical outcomes following infection with *Orientia tsutsugamushi*.

PLoS Negl Trop Dis. 2022;16(11):e0010459.

50.   Jiang L, Morris EK, Aguilera-Olvera R, Zhang Z, Chan TC, Shashikumar S, et al.

Dissemination of *Orientia tsutsugamushi*, a Causative Agent of Scrub Typhus, and

Immunological Responses in the Humanized DRAGA Mouse. Front Immunol. 2018;9:816.

51.   Kundavaram AP, Jonathan AJ, Nathaniel SD, Varghese GM. Eschar in scrub typhus: a

valuable clue to the diagnosis. J Postgrad Med. 2013;59(3):177-8.

52.   Paris DH, Phetsouvanh R, Tanganuchitcharnchai A, Jones M, Jenjaroen K, Vongsouvath

M, et al. *Orientia tsutsugamushi* in human scrub typhus eschars shows tropism for dendritic cells

and monocytes rather than endothelium. PLoS Negl Trop Dis. 2012;6(1):e1466.

53.   Park J, Woo SH, Lee CS. Evolution of Eschar in Scrub Typhus. Am J Trop Med Hyg.

2016;95(6):1223-4.

54.   Sonthayanon P, Chierakul W, Wuthiekanun V, Phimda K, Pukrittayakamee S, Day NP, et

al. Association of high *Orientia tsutsugamushi* DNA loads with disease of greater severity in

adults with scrub typhus. J Clin Microbiol. 2009;47(2):430-4.

55.   Chauhan V, Thakur A, Thakur S. Eschar is associated with poor prognosis in scrub

typhus. Indian J Med Res. 2017;145(5):693-6.

56.   Kitano T, Yamada H, Kida M, Okada Y, Saika S, Yoshida M. Impaired Healing of a

Cutaneous Wound in an Inducible Nitric Oxide Synthase-Knockout Mouse. Dermatol Res Pract.

2017;2017:2184040.

57.   Anh Phuong Luu AAG, Alexis Bouin, Nir Drayman, Thomas P. Burke. Differences

between human and rodent nitric oxide production dictate susceptibility to tick-borne Rickettsia.

bioRxiv [Preprint]. 2025 Jun 29:2025.06.27.661835.

58.   Hsu YH, Chen HI. Pulmonary pathology in patients associated with scrub typhus.

Pathology. 2008;40(3):268-71.

59.   Chauhan R, Ahmad S, Goyal C, Tewatia P. Hepatopathy in Scrub Typhus: Clinical

Presentation, Association With Morbidity and Impact on Outcome. Cureus. 2024;16(1):e52316.

60.   Neyaz Z, Bhattacharya V, Muzaffar N, Gurjar M. Brain MRI findings in a patient with

scrub typhus infection. Neurol India. 2016;64(4):788-92.

61.   Chung DR, Lee YS, Lee SS. Kinetics of inflammatory cytokines in patients with scrub

typhus receiving doxycycline treatment. J Infect. 2008;56(1):44-50.

62.   Paris DH, Chansamouth V, Nawtaisong P, Lowenberg EC, Phetsouvanh R, Blacksell SD,

et al. Coagulation and inflammation in scrub typhus and murine typhus--a prospective

comparative study from Laos. Clin Microbiol Infect. 2012;18(12):1221-8.

63.   Pulla P. Disease sleuths unmask deadly encephalitis culprit. Science.

2017;357(6349):344.

64.   Mittal M, Thangaraj JWV, Rose W, Verghese VP, Kumar CPG, Mittal M, et al. Scrub

Typhus as a Cause of Acute Encephalitis Syndrome, Gorakhpur, Uttar Pradesh, India. Emerg

Infect Dis. 2017;23(8):1414-6.

65.   Basu S, Chakravarty A. Neurological Manifestations of Scrub Typhus. Curr Neurol

Neurosci Rep. 2022;22(8):491-8.

66.   Garg D, Manesh A. Neurological Facets of Scrub Typhus: A Comprehensive Narrative

Review. Ann Indian Acad Neurol. 2021;24(6):849-64.

67.   Fisher J, Card G, Soong L. Neuroinflammation associated with scrub typhus and spotted

fever group rickettsioses. PLoS Negl Trop Dis. 2020;14(10):e0008675.

68.   Soong L, Shelite TR, Xing Y, Kodakandla H, Liang Y, Trent BJ, et al. Type 1-skewed

neuroinflammation and vascular damage associated with *Orientia tsutsugamushi* infection in

mice. PLoS Negl Trop Dis. 2017;11(7):e0005765.

69.   Prakash Gangwar S, Thangaraj JWV, Zaman K, Vairamani V, Mittal M, Murhekar M.

Sequelae Following Acute Encephalitis Syndrome Caused by *Orientia Tsutsugamushi*. Pediatr

Infect Dis J. 2020;39(5):e52-e4.

70.   Kim J, Seok H, Jeon JH, Choi WS, Seo GH, Park DW. Association of scrub typhus with

incidence of dementia: a nationwide population-based cohort study in Korea. BMC Infect Dis.

2023;23(1):127.

71.   Paris DH, Jenjaroen K, Blacksell SD, Phetsouvanh R, Wuthiekanun V, Newton PN, et al.

Differential patterns of endothelial and leucocyte activation in 'typhus-like' illnesses in Laos and

Thailand. Clin Exp Immunol. 2008;153(1):63-7.

72.   Tantibhedhyangkul W, Matamnan S, Longkunan A, Boonwong C, Khowawisetsut L.

Endothelial Activation in *Orientia tsutsugamushi* Infection Is Mediated by Cytokine Secretion

From Infected Monocytes. Front Cell Infect Microbiol. 2021;11:683017.

73.   Sporn LA, Lawrence SO, Silverman DJ, Marder VJ. E-selectin-dependent neutrophil

adhesion to Rickettsia rickettsii-infected endothelial cells. Blood. 1993;81(9):2406-12.

74.   Schoggins JW. Interferon-Stimulated Genes: What Do They All Do? Annu Rev Virol.

2019;6(1):567-84.

75.   Schneider WM, Chevillotte MD, Rice CM. Interferon-stimulated genes: a complex web

of host defenses. Annu Rev Immunol. 2014;32:513-45.

76.   Manful EE, Pietersen RD, Baker B. IFIT2-induced transcriptomic changes in

Mycobacterium tuberculosis infected macrophages. Front Cell Infect Microbiol.

2025;15:1536446.

77.   Lin Q, Rong L, Jia X, Li R, Yu B, Hu J, et al. IFN-gamma-dependent NK cell activation

is essential to metastasis suppression by engineered *Salmonella*. Nat Commun. 2021;12(1):2537.

78.   Horowitz A, Stegmann KA, Riley EM. Activation of natural killer cells during microbial

infections. Front Immunol. 2012;2:88.

79.   Bian Y, Walter DL, Zhang C. Efficiency of Interferon-gamma in Activating Dendritic

Cells and Its Potential Synergy with Toll-like Receptor Agonists. Viruses. 2023;15(5):1198.

80.   Schoenborn JR, Wilson CB. Regulation of interferon-gamma during innate and adaptive

immune responses. Adv Immunol. 2007;96:41-101.

A Body weight changes

B Disease severity

C Skin eschar lesion

D Skin eschar lesion size

E Skin eschar histology

A

Brain

Mouse *Ifngr1*

- WT
- Humanized

Relative fold changes

2.0 1.5 1.0 0.5 0.0

Uninfected   Infected

Mouse *Ifngr2*

Relative fold changes

2.0 1.5 1.0 0.5 0.0

Uninfected   Infected

Human *Ifngr1*

Relative fold changes

1.5 1.0 0.5 0.0

Uninfected   Infected

Human *Ifngr2*

Relative fold changes

1.5 1.0 0.5 0.0

Uninfected   Infected

B

Lung

Mouse *Ifngr1*

Relative fold changes

1.5 1.0 0.5 0.0

Uninfected   Infected

Mouse *Ifngr2*

Relative fold changes

1.5 1.0 0.5 0.0

Uninfected   Infected

Human *Ifngr1*

Relative fold changes

1.5 1.0 0.5 0.0

Uninfected   Infected

Human *Ifngr2*

Relative fold changes

1.5 1.0 0.5 0.0

Uninfected   Infected

C

Human IFN-γ ELISA

Concentration (pg/mL)

6000 4000 2000 0

- WT
- Humanized

****

u.d.   u.d.

Uninfected   Infected